World Pharma Today

  Unsorted Symeres, a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announces the acquisition of DGr Pharma, a drug development-focused consultancy, to expand its integrated early-stage drug development services and accelerate IND-enabling capabilities for biopharma clients. The acquisition is supported by Keensight Capital (“Keensight”), one of the leading private equity managers dedicated to pan-European Growth Buyout[[1]] investments. Founded in 2018 and based in the Netherlands, DGr Pharma specialises in pre-clinical and clinical regulatory strategy and consultancy for biotech and pharmaceutical partners working in early drug development. Its core services include chemical-pharmaceutical, non-clinical and clinical development planning, quality assurance, and regulatory submissions. DGr Pharma has deep expertise in small and large molecules including antibodies, ADCs and oligonucleotides. With a reputation for scientific rigor, DGr Pharma ...

  The Future of Clinical Trials: Integrating Technology and patient Experience In this engaging interview, Edward Bartles, Associate Director of Solution Engineering at IQVIA, discusses the impact of digital health technologies and wearables on the clinical trials landscape. The conversation covers IQVIA’s strategic approach to embedding digital tools in the research process—from electronic clinical outcome assessments (eCOA) and IoT platforms to global device sourcing and real-time data collection. Edward explains how adopting e-consenting, connected devices, and flexible trial design reduces patient burden and improves engagement across multi-region Phase III studies. https://www.youtube.com/watch?v=S0nhMq5eils&t=39s Special emphasis is given to regulatory trends, including decentralized trial implementation, EU clinical trials regulation, and the increasing flexibility behind trial methodology. The discussion highlights the importance of ensuring data quality, adaptability, ...

Note* — All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company. China’s biotech sector is now a key driver of innovation across global pipelines, as CPHI Shenzhen prepares for largest ever influx of foreign dealmakers Sino-international trade is accelerating as CPHI & PMEC China (June 24–26, 2025) reported a record-breaking international attendance, with a 30% year-on-year increase. The sharp uptick reflects surging demand from Western pharma, with China-based biotech in-licensing fuelling global pipelines, and wider partnering in China. Remarkably, international executives now account for nearly quarter of all visitors, with over 15,000 being international, led by rapid growth from Europe and the United States. Asia’s largest pharmaceutical event welcomed 109,056 attendees from 147 countries and 3,600 exhibitors across 240,000+ square meters, reinforcing its position as the largest and most globa...